Dr. Damodaran is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-745-7296
Education & Training
Ohio State University HospitalFellowship, Breast Medical Oncology, 2013 - 2015- Ohio State University HospitalPost-Doctoral Fellowship, Hematology and Medical Oncology, 2012 - 2015
- Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2013
University at BuffaloResidency, Internal Medicine, 2008 - 2011
University at BuffaloPhD, Biomedical Sciences, 2002 - 2008
Madras Medical CollegeClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2015 - 2026
OK State Medical License 2020 - 2021
OH State Medical License 2011 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Award American Society of Clinical Oncology, 2014
- Pelotonia Postdoctoral Award James Cancer Hospital and Solove Research Institute, 2014
- Obrine Weaver Award Ohio State University College of Medicine, 2013
- Join now to see all
Clinical Trials
- Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Start of enrollment: 2013 Oct 02
- Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing Start of enrollment: 2013 Nov 04
- Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. Start of enrollment: 2015 Feb 24
- Join now to see all
Publications & Presentations
PubMed
- 129 citationsNeoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.Jennifer K. Litton, Marion E. Scoggins, Kenneth R. Hess, Beatriz E. Adrada, Rashmi Krishna Murthy
Journal of Clinical Oncology. 2020-02-10 - 21 citationsPalbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the se...Min Jin Ha, Akshara Singareeka Raghavendra, Nicole M Kettner, Wei Qiao, Senthil Damodaran
International Journal of Cancer. 2022-06-15 - 45 citationsClinical tumor sequencing: opportunities and challenges for precision cancer medicine.Senthilkumar Damodaran, Michael F. Berger, Sameek Roychowdhury
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2015-01-01
Journal Articles
- Genomics and Precision Cancer MedicineDamodaran S and Roychowdhury S, Oncology and Hematology Review
- Endocrine resistance: mechanisms and therapeutic targetsDamodaran S, Majumder S, Ramaswamy R, Clinical Investigation
Books/Book Chapters
Press Mentions
Online Database Helps Organize Clinically Important Cancer Gene MutationsSeptember 8th, 2015
Grant Support
- Pelotonia Postdoctoral AwardOhio State UniversityPresent
- Obrine Weaver AwardOhio State UniversityPresent
- Young Investigator AwardASCO Conquer Cancer FoundationPresent
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
